Figure 5

Therapeutic efficacy of E-cadherin + DCs on lung tumour-bearing mice. (A) Changes in the tumour size in subcutaneous lung tumour-bearing mice. The tumour diameters (width*length) were measured using callipers every 2–3 days for the subcutaneous tumour model after E-cadherin + DCs were injected (each group n = 11). The mean size of the subcutaneous tumours of the mice that developed tumours in each group after tumour challenge. Three individual mice per group were analysed. In the E-cadherin + DC group, tumour volume decreased significantly compared with the E-cadherin- DC group. In the E-cadherin + DC and E-cadherin- DC groups, tumour volume increased slower than in the PBS group. (B) Survival curves of the subcutaneous tumour-bearing mice (each group n = 11). The E-cadherin + DC groups survived longer than the E-cadherin- DC groups, and both the E-cadherin + DC and E-cadherin- DC group survived longer than the PBS group. (C) Survival curves of the orthotopic lung tumour-bearing mice (each group n = 9). The E-cadherin + DC group survived longer than the E-cadherin- DC group, and both the E-cadherin + DC and E-cadherin- DC groups survived longer than the PBS group. Each experiment was performed in triplicate. The data were analysed by Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001).